“There's a lot that urologists can pick up on how to better interact with their patients,” says David King Keller, PhD, of Active Surveillance Patients International.
In this video, David King Keller, PhD, of Active Surveillance Patients International (www.aspatients.org), discusses the organization’s upcoming webinar, “The Leading Edge of Active Surveillance for Patients and Urologists,” featuring Eric Klein, MD, on July 31.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.